“Despite the variability of the path of the pandemic, we expect Veclury's important role to continue.”

In context

“40 million reflect continued early momentum in the launch of PBC, and we're proud of the market share we've achieved so far. Also pleased that in February, the European Commission granted conditional marketing authorization for Libdelzi. We have just launched in Germany a few weeks ago, and we expect to expand into other major European markets in the coming months. Moving to slide 11, Veclury sales of $302 million were down 45% year over year and 10% quarter over quarter, reflecting lower rates of COVID-19 related hospitalizations due to a milder winter season. Veclury's consistently high share of over sixty percent of treated hospitalized patients in the US reinforces its clinical benefit and position as the standard of care, particularly among patients with renal and hepatic impairment. Despite the variability of the path of the pandemic, we expect Veclury's important role to continue. On slide 12, Trodelvy sales of $293 million were down 5% year over year, reflecting inventory dynamics and lower average realized price, partially offset by higher demand. Sequentially, sales were down 17%, primarily driven by inventory dynamics and lower demand. Trodelvy remains the leading regimen in second-line metastatic triple-negative breast cancer in both the United States and Europe, with stable share in pretreated HR HER2 negative metastatic breast cancer. We also look forward to potentially bringing the benefits of Trodelvy to triple-negative breast cancer patients in earlier lines of treatment, given the clinically meaningful progression-free survival benefits seen in the ASCENT-04, and with data from the ASCENT-03 expected later this quarter. These studies could further streng”